Cargando…

The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families

OBJECTIVE: Approximately 5%–10% of breast cancer (BC) patients display familial traits that are genetically inherited among the members of a family. The purpose of this study was to profile the germline mutations in 43 genes with different penetration rates and their correlations with phenotypic tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Li, Zhang, Hailian, Zhang, Huan, Ye, Yingnan, Cheng, Yanan, Li, Lijuan, Wei, Lijuan, Han, Lei, Cao, Yandong, Li, Shixia, Hao, Xishan, Liu, Juntian, Yu, Jinpu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257317/
https://www.ncbi.nlm.nih.gov/pubmed/34570441
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0011
Descripción
Sumario:OBJECTIVE: Approximately 5%–10% of breast cancer (BC) patients display familial traits that are genetically inherited among the members of a family. The purpose of this study was to profile the germline mutations in 43 genes with different penetration rates and their correlations with phenotypic traits in Chinese familial BC families. METHODS: Ion Torrent S5™-based next generation sequencing was conducted on 116 subjects from 27 Chinese familial BC families. RESULTS: Eighty-one germline mutations in 27 BC predisposition genes were identified in 82.8% (96/116) of the cases. Among these, 80.8% of the mutated genes were related to DNA damage repair. Fourteen possible disease-causing variants were identified in 13 of 27 BC families. Only 25.9% (7/27) of the BC families exhibited hereditary deficiency in BRCA1/2 genes, while 22.2% of the BC families exhibited defects in non-BRCA genes. In all, 41.7% (40/96) of the mutation carriers had BRCA mutations, 88.5% (85/96) had non-BRCA mutations, and 30.2% (29/96) had both BRCA and non-BRCA mutations. The BC patients with BRCA mutations had a higher risk of axillary lymph node metastases than those without mutations (P < 0.05). However, the BC patients with non-BRCA mutations frequently had a higher occurrence of benign breast diseases than those without mutations (P < 0.05). CONCLUSIONS: In addition to BRCA1/2, genetic variants in non-BRCA DNA repair genes might play significant roles in the development of familial/hereditary BC. Therefore, profiling of multiple BC predisposition genes should be more valuable for screening potential pathogenic germline mutations in Chinese familial/hereditary BC.